Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Phase 3 Study of RPC1063 in Relapsing MS
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Pharmacokinetics of CAMPATH-1H in BMT patients.
The epidemiology of multiple sclerosis in three Australian cities: Perth, Newcastle and Hobart.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.

Pages